Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics
One of the most pressing challenges associated with SARS-CoV-2 treatment is the emergence of new variants that may be more transmissible, cause more severe disease, or be resistant to current treatments and vaccines. The emergence of SARS-CoV-2 has led to a global pandemic, resulting in millions of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223008909 |
| _version_ | 1797744049666392064 |
|---|---|
| author | Benjamin Ayodipupo Babalola Oluwamayowa Samuel Akinsuyi Elizabeth Oreoluwa Folajimi Folakemi Olujimi Ahmed Adebisi Otunba Bruno Chikere Ibitayo Ajayi Adewumagun Tosin Emmanuel Adetobi |
| author_facet | Benjamin Ayodipupo Babalola Oluwamayowa Samuel Akinsuyi Elizabeth Oreoluwa Folajimi Folakemi Olujimi Ahmed Adebisi Otunba Bruno Chikere Ibitayo Ajayi Adewumagun Tosin Emmanuel Adetobi |
| author_sort | Benjamin Ayodipupo Babalola |
| collection | DOAJ |
| description | One of the most pressing challenges associated with SARS-CoV-2 treatment is the emergence of new variants that may be more transmissible, cause more severe disease, or be resistant to current treatments and vaccines. The emergence of SARS-CoV-2 has led to a global pandemic, resulting in millions of deaths worldwide. Various strategies have been employed to combat the virus, including neutralizing monoclonal antibodies (mAbs), CRISPR/Cas13, and antisense oligonucleotides (ASOs). While vaccines and small molecules have proven to be an effective means of preventing severe COVID-19 and reducing transmission rates, the emergence of new virus variants poses a challenge to their effectiveness. Monoclonal antibodies have shown promise in treating early-stage COVID-19, but their effectiveness is limited in severe cases and the emergence of new variants may reduce their binding affinity. CRISPR/Cas13 has shown potential in targeting essential viral genes, but its efficiency, specificity, and delivery to the site of infection are major limitations. ASOs have also been shown to be effective in targeting viral RNA, but they face similar challenges to CRISPR/Cas13 in terms of delivery and potential off-target effects. In conclusion, a combination of these strategies may provide a more effective means of combating SARS-CoV-2, and future research should focus on improving their efficiency, specificity, and delivery to the site of infection. It is evident that the continued research and development of these alternative therapies will be essential in the ongoing fight against SARS-CoV-2 and its potential future variants. |
| first_indexed | 2024-03-12T15:05:08Z |
| format | Article |
| id | doaj.art-317179b1ec3541a0831adb5fffd80844 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-12T15:05:08Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-317179b1ec3541a0831adb5fffd808442023-08-13T04:52:35ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-09-01165115099Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeuticsBenjamin Ayodipupo Babalola0Oluwamayowa Samuel Akinsuyi1Elizabeth Oreoluwa Folajimi2Folakemi Olujimi3Ahmed Adebisi Otunba4Bruno Chikere5Ibitayo Ajayi Adewumagun6Tosin Emmanuel Adetobi7Department of Chemistry, Purdue University, West Lafayette, IN, USA; Corresponding author.Department of Microbiology and Cell Science, University of Florida, Gainsville, FL, USADepartment of Microbiology, University of Ilorin, Ilorin, Kwara State, NigeriaDepartment of Biochemistry, Mountain Top University, Prayer-City, Ogun State, NigeriaDaniel and Fola Biotechnology Foundation, Makoko, Lagos State, NigeriaDepartment of Biochemistry, Covenant University, Ogun State, NigeriaDepartment of Biochemistry, Covenant University, Ogun State, NigeriaDepartment of Anatomy, University of Ilorin, Ilorin, Kwara State, NigeriaOne of the most pressing challenges associated with SARS-CoV-2 treatment is the emergence of new variants that may be more transmissible, cause more severe disease, or be resistant to current treatments and vaccines. The emergence of SARS-CoV-2 has led to a global pandemic, resulting in millions of deaths worldwide. Various strategies have been employed to combat the virus, including neutralizing monoclonal antibodies (mAbs), CRISPR/Cas13, and antisense oligonucleotides (ASOs). While vaccines and small molecules have proven to be an effective means of preventing severe COVID-19 and reducing transmission rates, the emergence of new virus variants poses a challenge to their effectiveness. Monoclonal antibodies have shown promise in treating early-stage COVID-19, but their effectiveness is limited in severe cases and the emergence of new variants may reduce their binding affinity. CRISPR/Cas13 has shown potential in targeting essential viral genes, but its efficiency, specificity, and delivery to the site of infection are major limitations. ASOs have also been shown to be effective in targeting viral RNA, but they face similar challenges to CRISPR/Cas13 in terms of delivery and potential off-target effects. In conclusion, a combination of these strategies may provide a more effective means of combating SARS-CoV-2, and future research should focus on improving their efficiency, specificity, and delivery to the site of infection. It is evident that the continued research and development of these alternative therapies will be essential in the ongoing fight against SARS-CoV-2 and its potential future variants.http://www.sciencedirect.com/science/article/pii/S0753332223008909SARS-CoV-2Antiviral alternativesAntisense oligonucleotidesNeutralizing monoclonal antibodiesCRISPR/Cas |
| spellingShingle | Benjamin Ayodipupo Babalola Oluwamayowa Samuel Akinsuyi Elizabeth Oreoluwa Folajimi Folakemi Olujimi Ahmed Adebisi Otunba Bruno Chikere Ibitayo Ajayi Adewumagun Tosin Emmanuel Adetobi Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics Biomedicine & Pharmacotherapy SARS-CoV-2 Antiviral alternatives Antisense oligonucleotides Neutralizing monoclonal antibodies CRISPR/Cas |
| title | Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics |
| title_full | Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics |
| title_fullStr | Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics |
| title_full_unstemmed | Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics |
| title_short | Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics |
| title_sort | exploring the future of sars cov 2 treatment after the first two years of the pandemic a comparative study of alternative therapeutics |
| topic | SARS-CoV-2 Antiviral alternatives Antisense oligonucleotides Neutralizing monoclonal antibodies CRISPR/Cas |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223008909 |
| work_keys_str_mv | AT benjaminayodipupobabalola exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics AT oluwamayowasamuelakinsuyi exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics AT elizabethoreoluwafolajimi exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics AT folakemiolujimi exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics AT ahmedadebisiotunba exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics AT brunochikere exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics AT ibitayoajayiadewumagun exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics AT tosinemmanueladetobi exploringthefutureofsarscov2treatmentafterthefirsttwoyearsofthepandemicacomparativestudyofalternativetherapeutics |